RCT: Ravidasvir plus sofosbuvir are effective and well tolerated in patients with chronic HCV infection, with potential as an affordable treatment for these patients

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial – The Lancet Gastroenterology & Hepatology

Commentary on Twitter

Trial results of new affordable #hepatitisC treatment showing 97% cure rate now published in @LancetGastroHep!

Ravidasvir + sofosbuvir has the potential to provide an additional affordable, simple, and efficacious #publichealth tool to eliminate HCV.

➡️https://t.co/Oo1ZHQnyn6 pic.twitter.com/FcFntfYMSC

— Drugs for Neglected Diseases initiative (@DNDi) April 16, 2021